Use of memantine in the preparation of a medicament for preventing and / or treating small cell lung cancer expressing grm2a
By detecting the expression of GluN2A protein in patients with small cell lung cancer, patients suitable for mimantine targeted therapy were screened, and mimantine drugs were developed, which solved the problems of recurrence and drug resistance in small cell lung cancer and achieved a highly efficient and safe targeted therapy effect.
Patent Information
- Application Number
- CN202610665842.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-14
- Publication Date
- 2026-07-17
AI Technical Summary
Current technologies lack effective targeted drugs and precise screening criteria for applicable populations, leading to severe recurrence and drug resistance in small cell lung cancer, resulting in extremely low five-year survival rates for patients. Traditional non-selective drug therapy lacks targeting and is difficult to treat effectively.
Using GluN2A protein as a biomarker, this study screens patients suitable for meimantine targeted therapy by detecting whether GluN2A protein is expressed in small cell lung cancer patient samples, and develops meimantine as a drug for the prevention and treatment of small cell lung cancer expressing GRIN2A.
It significantly inhibits the viability, clonogenic ability, DNA replication activity and migration ability of small cell lung cancer cells, destroys 3D tumor spheroids, reduces the volume and weight of xenograft tumors, improves treatment efficiency, and provides a new drug solution. It has the characteristics of strong pharmacological effects, clear targeting and good safety.
Smart Images
Figure CN122410031A_ABST